Sepsis Phenotypes

Value of the Information & Strength of the Argument

The talk provides a high-value synthesis of current knowledge on sepsis phenotyping, integrating clinical and molecular approaches. The argumentation is solid, grounded in published trials and ongoing research. The speaker clearly explains the rationale for predictive enrichment and illustrates it with concrete examples, showing how biomarkers can guide therapy selection. He also addresses the challenges of heterogeneity and the need for consensus in endotyping. The presentation is well-structured and logically progresses from pathophysiology to clinical applications.

The title accurately reflects the content, which focuses on sepsis phenotypes and their clinical implications.

8/10

Presentation by a leading expert in sepsis research, based on published studies and ongoing research, with clear methodology and references to key trials.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to sepsis definition and heterogeneity
• 05:00Overview of subphenotypes based on clinical data
• 10:00Explanation of host response and immune dysregulation
• 15:00Discussion of failed immunomodulatory trials and need for enrichment
• 20:00Predictive enrichment examples: ASTONISH trial and IL-7
• 25:00Stratification based on ferritin and HLA-DR: personalized approach
• 30:00Unbiased phenotyping using blood transcriptomics: MARS and SRS
• 35:00Consensus endotypes (CTS1-3) and their prognostic value
• 40:00ARDS phenotypes and their validation in sepsis
• 45:00New DIP score based on plasma biomarkers

• Sepsis 3.0 definition (JAMA 2016) — Definition of sepsis as life-threatening organ dysfunction caused by dysregulated host response.
• Seymour et al. JAMA 2019 - Sepsis phenotypes — Identification of alpha, beta, gamma, delta phenotypes based on clinical data.
• ASTONISH trial (TREM-1 inhibitor) — Trial using soluble TREM-1 as predictive enrichment for TREM-1 inhibitor.
• IL-7 trial in septic shock with lymphocytopenia — Trial showing IL-7 increases lymphocyte counts in patients with lymphocytopenia.
• Interferon-gamma and anakinra trial in sepsis — Small trial stratifying patients based on ferritin and HLA-DR.
• MARS phenotypes (Scicluna et al. 2015) — Identification of four molecular subtypes in sepsis using blood transcriptomics.
• SRS endotypes (Davenport et al. 2016) — Sepsis response signature endotypes.
• Consensus endotypes (Nature Medicine 2024) — Consensus blood transcriptomic endotypes (CTS1-3) across three cohorts.
• VANISH trial (hydrocortisone in septic shock) — Trial showing harm in CTS2 patients treated with hydrocortisone.
• ARDS phenotypes (Calfee et al. 2014) — Identification of hyper- and hypoinflammatory ARDS phenotypes.
• PROWESS trial (activated protein C) — Trial showing benefit in hyperinflammatory phenotype.

• Sepsis endotypes and precision medicine — Consensus endotypes align with the talk's emphasis on harmonization.
• ARDS phenotypes and sepsis — Calfee's phenotypes are validated in sepsis, supporting the talk's discussion.

• Some trials have not shown benefit despite enrichment — The talk acknowledges that many trials have failed, and even with enrichment, some therapies may not work.